keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Methyllycaconitine citrate (MLA) is an α7 neuronal nicotinic acetylcholine receptor (α7nAChR) antagonist that crosses the blood-brain barrier.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 40.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 39.00 |
Description | Methyllycaconitine citrate (MLA) is an α7 neuronal nicotinic acetylcholine receptor (α7nAChR) antagonist that crosses the blood-brain barrier. |
In vitro | Pretreatment with 5 and 10 µM Methyllycaconitine citrate inhibited the decreased cell viability induced by Aβ25–35, which suggested that Methyllycaconitine citrate had a protective effect against Aβ-induced cytotoxicity. Furthermore, cell viability did not decrease after exposure to Methyllycaconitine citrate (2.5, 5, 10, 20 uM), which suggests a good safety profile[1]. |
In vivo | The effect of MLA on acute METH-induced effects and neurotoxicity in mice was tested using an in vivo model. The results indicate that MLA (6 mg/kg) inhibited 50% of the METH-induced climbing behavior[2]. |
Synonyms | MLA |
Molecular Weight | 874.92 |
Formula | C43H58N2O17 |
CAS No. | 351344-10-0 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (114.30 mM), Sonification is recommended.
H2O: 1 mg/mL (1.14 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Methyllycaconitine citrate 351344-10-0 Neuroscience AChR MLA inhibitor inhibit